Objective: Termination of pregnancy in the 2/3 trimester for fetal or maternal complications (i.e., for medical reasons) is an essential health service. We aimed to describe the systems-level pathways for this care in Canada.

Methods: We conducted one-on-one semi-structured interviews with maternal fetal medicine (MFM), medical genetics, and nursing/social work clinicians at the 10 academic MFM sites in Canada. We conducted qualitative content analysis to identify categories describing the clinical care pathway. We triangulated data from participants within sites, and then compared data across sites to describe similarities and differences in care. We used NVivo14 Software for coding.

Results: We recruited 28 participants representing all sites - 10 MFM specialists, 9 medical geneticists/genetic counsellors, and 9 nurses/social workers. We identified 4 main categories describing the clinical care pathway: (1) initial visit and clinic structure, (2) offering termination, (3) provision of procedural and medication termination, and (4) post-termination care. Across sites, although clinic structure and post-termination care were similar, there were differences in offering the option of termination (e.g. variable indications qualifying for approval), and variation in details regarding the provision of procedural and medical termination (e.g. upper gestational age limits for procedural versus medical approaches).

Conclusions: Clinical care pathways for 2/3 trimester termination for medical reasons are variable across Canadian academic MFM centres, especially regarding circumstances under which termination is offered and details regarding the provision of procedural and medical termination. These differences provide opportunities to inform efforts to optimize equitable and comprehensive services in Canada.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jogc.2025.102770DOI Listing

Publication Analysis

Top Keywords

clinical care
16
medical reasons
12
provision procedural
12
termination
9
care pathways
8
trimester termination
8
termination pregnancy
8
medical
8
2/3 trimester
8
academic mfm
8

Similar Publications

In 2017, Kidney Disease: Improving Global Outcomes (KDIGO) published a Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Since then, new lines of evidence have been published related to evaluating disordered mineral metabolism and bone quality and turnover, identifying and inhibiting vascular calcification, targeting vitamin D levels, and regulating parathyroid hormone. For an in-depth consideration of the new insights, in October 2023, KDIGO held a Controversies Conference on CKD-MBD: Progress and Knowledge Gaps Toward Personalizing Care.

View Article and Find Full Text PDF

ISCT MSC committee statement on the US FDA approval of allogenic bone-marrow mesenchymal stromal cells.

Cytotherapy

January 2025

Osteoarthritis Research Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada; Krembil Research Institute, University Health Network, Toronto, Ontario, Canada; Institute of Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, Division of Hematology, University of Toronto, Toronto, Ontario, Canada. Electronic address:

The December 2024 US Food and Drug Administration (FDA) approval of Mesoblast's Ryoncil (remestemcel-L-rknd)-allogeneic bone marrow mesenchymal stromal cell (MSC(M)) therapy-in pediatric acute steroid-refractory graft-versus-host-disease finally ended a long-lasting drought on approved MSC clinical products in the United States. While other jurisdictions-including Europe, Japan, India, and South Korea-have marketed autologous or allogeneic MSC products, the United States has lagged in its approval. The sponsor's significant efforts and investments, working closely with the FDA addressing concerns regarding clinical efficacy and consistent MSC potency through an iterative process that spanned several years, was rewarded with this landmark approval.

View Article and Find Full Text PDF

Evaluating Clinician Experience in Health Care Transition: Results From Six Health Systems.

J Adolesc Health

January 2025

The National Alliance to Advance Adolescent Health/Got Transition, Washington, D.C.

Purpose: There is a paucity of evidence examining clinician experiences with structured health-care transition (HCT) programs. Among HCT Learning Collaborative participants, this study describes clinician experiences with implementation of a structured HCT process: Got Transition's 6 Core Elements.

Methods: Representative members from 6 health systems designed a survey to collect clinician feedback regarding HCT and demographic and practice information.

View Article and Find Full Text PDF

Adaptive immune resistance in cancer describes the various mechanisms by which tumors adapt to evade anti-tumor immune responses. IFN-γ induction of programmed death-ligand 1 (PD-L1) was the first defined and validated adaptive immune resistance mechanism. The endoplasmic reticulum (ER) is central to adaptive immune resistance as immune modulatory secreted and integral membrane proteins are dependent on ER.

View Article and Find Full Text PDF

Advances in Diagnosis, Treatment and Prognostic in Aortoiliac Occlusive Disease - A Narrative Review.

Port J Card Thorac Vasc Surg

January 2025

Department of Biomedicine - Unit of Anatomy, Faculty of Medicine, University of Porto; RISE@Health, Porto, Portugal.

Background: Aortoiliac disease (AID) is a variant of peripheral artery disease involving the infrarenal aorta and iliac arteries. Similar to other arterial diseases, aortoiliac disease obstructs blood flow through narrowed lumens or by embolization of plaques. AID, when symptomatic, may present with a triad of claudication, impotence, and absence of femoral pulses, a triad also referred as Leriche Syndrome (LS).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!